论文部分内容阅读
目的:比较贝那普利分别与苯磺酸左旋氨氯地平或硝苯地平缓释片合用,治疗单用贝那普利不能控制其血压降至目标水平的原发性高血压患者的疗效、不良反应。方法:112例单用贝那普利治疗不能控制其理想血压的患者分成2组,在贝那普利原有剂量不变下,分别加用苯磺酸左旋氨氯地平或硝苯地平缓释片治疗,用药4-6 wk后判断降压疗效并记录不良反应。结果:加用苯磺酸左旋氨氯地平后有效率为85.71％,加用硝苯地平缓释片后为78.57％,2组疗效比较无统计学意义(P>0.05),加用苯磺酸左旋氨氯地平后的显效率(73.21％)高于加用硝苯地平缓释片(54.38％,P<0.05),降SBP的幅度显著大于加用硝苯地平缓释片(P<0.01),且不良反应显著低于加用硝苯地平组(8.93％ vs 28.5％,P<0.01)。结论:对单用贝那普利治疗不能控制至理想血压的患者,贝那普利合用苯磺酸左旋氨氯地平或硝苯地平缓释片治疗都是有效的。从对血压的降低水平、对SBP的显效率和不良事件的发生率综合评价,贝那普利和苯磺酸左旋氨氯地平联合更适合于此类患者的治疗。
OBJECTIVE: To compare the efficacy of benazepril with either levamlodipine besylate or nifedipine sustained-release tablets alone in the treatment of patients with essential hypertension who are unable to control their blood pressure to a target level with benazepril alone, Adverse reactions. Methods: One hundred and twelve patients treated with benazepril alone could not be controlled their ideal blood pressure were divided into two groups, the original dose of benazepril unchanged, respectively, with levamlodipine besylate or nifedipine slow release Treatment, 4-6 wk medication to determine the efficacy of antihypertensive and record adverse reactions. Results: The effective rate of levamlodipine besylate was 85.71% and that of nifedipine sustained-release tablets was 78.57%. There was no significant difference between the two groups (P> 0.05) The effective rate of levamlodipine (73.21%) was higher than that of nifedipine extended release tablets (54.38%, P <0.05), and the decrease of SBP was significantly greater than that of nifedipine sustained release tablets (P <0.01) , And the adverse reaction was significantly lower than that of nifedipine plus group (8.93% vs 28.5%, P <0.01). CONCLUSIONS: Benapril combined with levamlodipine besylate or nifedipine sustained-release tablets was effective in patients who were unable to control their ideal blood pressure with benazepril alone. The combination of benazepril and levamlodipine besylate is more suitable for the treatment of such patients from a comprehensive assessment of the marked reduction in blood pressure, the apparent efficiency of SBP and the incidence of adverse events.